P1200Body composition parameters as predictors of clinical activity in patients with active Ulcerative Colitis

Abstract Background Inflammatory bowel disease (IBD), which includes Ulcerative Colitis (UC) and Crohn’s disease, is a chronic disorder affecting the mucosa of the colon and rectum, altering nutritional status, absorption, and body composition (1,2). During active flares, the release of pro-inflammatory cytokines induces a catabolic state that contributes to loss of muscle mass and malnutrition, negatively impacting prognosis and quality of life (3). Bioelectrical impedance analysis (BIA) has become a useful tool for assessing body composition parameters associated with nutritional status and clinical outcomes (4). Therefore, identifying body composition parameters that predict clinical response to disease activity could optimise interventions in patients with active UC, and the aim of this study is to evaluate these parameters as predictors of clinical activity in this population. Methods A prospective cohort study was conducted in patients ≥18 years with active UC treated at the IBD clinic of the Hospital General de México “Dr Eduardo Liceaga”. Patients were classified according to MAYO clinical activity (Table 1). A risk analysis (OR) was performed to estimate the strength of association between body composition parameters and the probability of clinical response to activity. Results A total of 34 patients were included (32% men and 68% women), of whom 41% were responders. No significant differences were found in body composition parameters between groups (Table 1). In the binary logistic regression, the fat mass index (FMI) was the only significant predictor of clinical response (OR = 46.7; 95% CI: 1.8–1205.3; p = 0.02). Skeletal muscle mass, phase angle, fibre intake, and total body water showed a mild positive trend (OR 1) without reaching statistical significance (Figure 1). The model demonstrated good fit (Hosmer–Lemeshow p = 0.407) and a classification accuracy of 73.5%. Conclusion The results suggest that FMI may be considered a positive predictive factor for clinical activity in patients with active UC. Although other body composition parameters showed clinical relevance, they did not reach statistical significance. These findings support the usefulness of bioelectrical impedance analysis as a tool to identify body characteristics associated with better clinical response, however, confirmation with larger samples and prospective designs is recommended. References: 1. Yamamoto-Furusho JK. Evaluación del estado nutricional y su asociación con el grado de actividad en pacientes mexicanos con colitis ulcerosa crónica idiopática (CUCI). Rev Gastroenterol Mex. 2021;86(2):107-109. 2. Vieujean S, Lindsay JO, D’Amico F, Ahuja V, Silverberg MS, Sood A, et al. Analysis of clinical trial screen failures in inflammatory bowel diseases: real-world results from the International Organization for the Study of IBD. J Crohns Colitis. 2023;18(4):548-559. 3. Diez-Martin E, Hernandez-Suarez L, Muñoz-Villafranca C, Martin-Souto L, Astigarraga E, Ramirez-Garcia A, et al. Inflammatory bowel disease: a comprehensive analysis of molecular bases, predictive biomarkers, diagnostic methods, and therapeutic options. Int J Mol Sci. 2024;25(13):7062. 4. Fernandes SA, Rossoni C, Koch VW, Imbrizi M, Evangelista-Poderoso R, Pinto LP, et al. Phase angle through electrical bioimpedance as a predictor of cellularity in inflammatory bowel disease. Artif Intell Gastroenterol. 2021;2(4):111. Conflict of interest: Mr. Baños Vazquez, Roberto: No conflict of interest Santoyo Chávez, Martha Alison: No conflict of interest Mendoza Martinez, Viridiana Montsserrat: No conflict of interest Rivera, Ernestina: No conflict of interest De Leon Rendon, Jorge Luis: Dr. Jorge Luis De León Rendón is a member of Advisory Boards, key opinion leader, and speaker for Abbvie Mexico, Takeda Mexico, and Janssen Mexico. He has served as a key opinion leader and lecturer for Schwabe Pharma Mexico, Servier, Pfizer, Alfasigma, and Siegfried Rhein Mexico. He has received support for research manuscript publication and editing from Takeda and Schwabe Pharma Mexico. Additionally, he has coordinated research studies and medical education programs with Shire, Bristol Myers Squibb, Takeda, Schwabe Pharma, Abbvie, Janssen, MSD, and Roche. Abarca Rojano, Edgar: No conflict of interest Carrillo Rojas, Javier Ivanovychs: No conflict of interest Varela Martinez, Yessica Nohemí: No conflict of interest Bueno Hernández, Nallely: No conflict of interest